With 5-0 Winning Streak, Bayer And J&J Move To Eliminate Remaining Xarelto Litigation
Firms want Fifth Circuit to review whether federal law preempts failure-to-warn and design-defect claims; ruling in their favor could end 20,000-plus pending US cases.
You may also be interested in...
Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.
Product Liability Returning To Supreme Court With Government, Former FDA Officials On Opposite Sides
US government supports Merck, saying FDA labeling decision preempts Fosamax failure-to-warn claim. Joshua Sharfstein and two other former FDAers argue Merck sought warning on a lesser injury.
For second time, judge finds problem with jury verdict against AbbVie; Bayer withdraws its appeal of Xarelto pre-trial rulings pending outcome of Supreme Court case.